Quick Answer
Silence Therapeutics plc reported Total Revenue of $559.0 thousand for fiscal year 2025.
Silence Therapeutics plc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $559.0K -98.7% |
$43.26M +36.7% |
$31.64M +46.1% |
$21.66M | — | — |
| Revenue (ASC 606) | $559.0K -98.7% |
$43.26M +36.7% |
$31.64M +46.1% |
$21.66M | — | — |
| Net Income | -$88.61M -95.6% |
-$45.31M +16.4% |
-$54.23M -7.7% |
-$50.33M | — | — |
| Diluted EPS | -$0.63 -90.9% |
-$0.33 +32.7% |
-$0.49 +5.8% |
-$0.52 | — | — |
| Total Assets | $131.44M -35.1% |
$202.63M +69.6% |
$119.45M | — | — | — |
| Cash and Equivalents | $11.28M -90.7% |
$121.33M +76.4% |
$68.79M | — | — | — |
| Stockholders Equity | $62.30M -53.5% |
$134.02M +509.4% |
$21.99M -19.2% |
$27.22M +120.0% |
$12.37M | — |
| R&D Expense | $67.75M -0.2% |
$67.88M +19.2% |
$56.94M +30.7% |
$43.55M +41.6% |
$30.77M +52.2% |
$20.21M +51.5% |
| Operating Income | -$91.08M -43.8% |
-$63.32M +1.7% |
-$64.38M -5.5% |
-$61.04M | — | — |
| Gross Profit | $344.0K -98.9% |
$31.45M +67.5% |
$18.78M +129.2% |
$8.19M +65.2% |
$4.96M +188.8% |
$1.72M +603.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $159.0K | -89.4% | -29.0% |
| Revenue (ASC 606) | September 30, 2025 | $159.0K | -89.4% | -29.0% |
| Net Income | September 30, 2025 | -$20.96M | +41.0% | +23.4% |
| Diluted EPS | September 30, 2025 | -$0.15 | +40.0% | +21.1% |
| Total Assets | September 30, 2025 | $146.79M | — | -11.2% |
| Cash and Equivalents | September 30, 2025 | $82.03M | — | +96.5% |
| Stockholders Equity | September 30, 2025 | $74.06M | -41.5% | -21.3% |
| R&D Expense | September 30, 2025 | $20.54M | +1.9% | +16.4% |
| Operating Income | September 30, 2025 | -$26.24M | +12.5% | -9.5% |
| Gross Profit | September 30, 2025 | $95.0K | +104.4% | -31.7% |
- Silence Therapeutics plc reported Total Revenue of $559.0 thousand for fiscal year 2025.
- Silence Therapeutics plc showed a decrease of -98.7% in Total Revenue compared to the prior fiscal year.
- Silence Therapeutics plc reported Revenue (ASC 606) of $559.0 thousand for fiscal year 2025.
- Silence Therapeutics plc showed a decrease of -98.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Silence Therapeutics plc reported Net Income of -$88.61 million for fiscal year 2025.
- Silence Therapeutics plc showed a decrease of -95.6% in Net Income compared to the prior fiscal year.
- Silence Therapeutics plc reported Diluted EPS of $0.63 per share (loss) for fiscal year 2025.
- Silence Therapeutics plc showed a decrease of -90.9% in Diluted EPS compared to the prior fiscal year.
- Silence Therapeutics plc reported Total Assets of $131.44 million for fiscal year 2025.
- Silence Therapeutics plc showed a decrease of -35.1% in Total Assets compared to the prior fiscal year.
- Silence Therapeutics plc reported Cash and Equivalents of $11.28 million for fiscal year 2025.
- Silence Therapeutics plc showed a decrease of -90.7% in Cash and Equivalents compared to the prior fiscal year.
- Silence Therapeutics plc reported Stockholders Equity of $62.30 million for fiscal year 2025.
- Silence Therapeutics plc showed a decrease of -53.5% in Stockholders Equity compared to the prior fiscal year.
- Silence Therapeutics plc reported R&D Expense of $67.75 million for fiscal year 2025.
- Silence Therapeutics plc showed a decrease of -0.2% in R&D Expense compared to the prior fiscal year.
- Silence Therapeutics plc reported Operating Income of -$91.08 million for fiscal year 2025.
- Silence Therapeutics plc showed a decrease of -43.8% in Operating Income compared to the prior fiscal year.
- Silence Therapeutics plc reported Gross Profit of $344.0 thousand for fiscal year 2025.
- Silence Therapeutics plc showed a decrease of -98.9% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: